Phase 1 Study of Fusilev® to Prevent or Reduce Mucositis in Patients With Non-Small Cell Lung Cancer Receiving Folotyn®

This is an open-label, uncontrolled, nonrandomized, multicenter, dose-finding, single-arm, Phase 1 study primarily to determine the optimal dose and schedule of Fusilev to prevent or reduce Folotyn-related Grade 3 or higher oral mucositis.

• Folotyn (Drug), also known as Pralatrexate: A cycle of Folotyn treatment is 28 days, with treatment on Days 1 and 15 in each cycle.
• Fusilev (Drug), also known as Levoleucovorin: Fusilev will be administered either four times a day (QID) (6 hours apart, ±10 minutes), twice a day (BID) (8 hours apart, ±10 minutes) or once a day (QD) by IV push (3-5 minutes) at a dose of 5 mg/m2 according to the cohort to which patients are assigned.

Primary outcomes

• Optimal dose and Schedule of Fusilev to prevent or reduce Oral Mucositis [Up to 8 weeks]: The study period will begin on the first day of Folotyn treatment (Day 1). Folotyn will be administered intravenously (IV) at a dose of 190 mg/m2 on Days 1 and 15 in a 28-day treatment cycle. Twenty-four hours after the Folotyn dose, Fusilev will be administered either four times a day (QID) (6 hours apart, ±10 minutes), twice a day (BID) (8 hours apart, ±10 minutes) or once a day (QD) by IV push (3-5 minutes) at a dose of 5 mg/m2 according to the cohort to which patients are assigned. Within a given cohort, Fusilev will be administered at the same dose and schedule after each Folotyn dose for the duration of the study.

Secondary outcomes

• Impact of Fusilev on the number of Folotyn-related dose modifications secondary to oral mucositis [Up to 8 weeks]: Analysis will involve the number, percent and type of Folotyn dose modification as a function of Fusilev dose.
• Impact of Fusilev on the frequency of Oral Mucositis [Up to 8 weeks]: Distribution of the number of cases of oral mucositis will be described by cohort and by degree of mucositis.
• Impact of Fusilev on use of Analgesics for Oral Mucositis [Up to 8 weeks]: Oral mucositis assessment form will be provided by the sponsor and is to be completed during treatment visits on day 1 \& 15, days 4 \&18, end of treatment visits. Patients will complete an Oral Mucositis Daily Questionnaire (OMDQ) starting at Day 1 of Cycle 1 and ending at the End of Treatment visit. Oral mucositis assessment will be assessed in the clinic by the investigator, or designee, and graded according to AE severity as established in the NCI CTCAE scale, Version 4.0.
• Impact of Fusilev on number of Folotyn doses delivered [Up to 8 weeks]: All treatment-emergent AEs will be managed per the investigator's judgment or the site's clinical standard of care. Folotyn decrease dose modifications will be made based on Hematologic Adverse Events (absolute neutrophil count) and Non- Hematologic Adverse events (CTCAE v.4) excluding nausea/vomiting for dose adjustments

Sex: All, ages: 18 Years to any

Inclusion Criteria:

* At least 18 years of age
* Relapsed or Refractory Non Small Cell Lung Cancer (NSCLC) after at least one line of therapy
* Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2
* Histologically or cytologically confirmed Stage III B/IV NSCLC
* Adequate hematological, hepatic, and renal function
* Available during the first 8 weeks of the study treatment period to visit the clinic for oral Mucositis assessments on scheduled days

Exclusion Criteria:

* Active concurrent malignancy. If there is a history of prior malignancies other than those exceptions listed above, the patient must be disease-free for at least 5 years
* Congestive heart failure
* Uncontrolled hypertension
* Known human immunodeficiency virus (HIV)-positive diagnosis
* Previous exposure to Pralatrexate
* Pregnant or breast-feeding women
* Major surgery within 14 days of enrollment
* Active uncontrolled infection, underlying medical condition, or other serious illness that would impair the ability of the patient to receive protocol treatment
* Symptomatic central nervous system (CNS) metastases or lesions for which treatment is required. Patients who received prophylactic CNS treatment are eligible